TL1A (TNFSF15) genotype affects the long-term therapeutic outcomes of anti-TNFα antibodies for Crohn's disease patients.

Katsuya Endo Yoichi KakutaRintaro MoroiKatsutoshi YamamotoHisashi ShigaMasatake KurohaTakeo NaitoYoshitaka KinouchiAtsushi Masamune

Published in: JGH open : an open access journal of gastroenterology and hepatology (2020)

An association was found between the TL1A genotype and the therapeutic outcomes of anti-TNF therapy. Our data indicate that the design of customized therapy with anti-TNF antibodies using TL1A genomic information could be effective in the future.

Keyphrases

rheumatoid arthritis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
healthcare
gene expression
mesenchymal stem cells
adipose tissue
genome wide
social media
health information
weight loss
replacement therapy
smoking cessation